PMID- 37772593
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231214
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 10
DP  - 2023 Oct
TI  - High-throughput Sequencing Analysis of Differentially Expressed microRNAs 
      Associated With SREBP1 in Differentiated Thyroid Carcinoma.
PG  - 4435-4446
LID - 10.21873/anticanres.16639 [doi]
AB  - BACKGROUND/AIM: MicroRNAs (miRNAs) interact with mRNAs and play important roles 
      in progression and prognosis in multiple cancers. Sterol regulatory 
      element-binding protein 1 (SREBP1) is an important lipid metabolism regulatory 
      gene. The aim of the present study was to analyze the profiles of miRNAs that are 
      associated with SREBP1 expression in differentiated thyroid carcinoma (DTC). 
      MATERIALS AND METHODS: In the present study, a high-throughput small RNA 
      sequencing (miRNA-Seq) method was used to investigate differences in miRNA 
      profiling with versus without interference with SREBP1 expression via small 
      interfering RNA. Real-time qPCR (qRT-PCR) was performed to confirm the results. 
      RESULTS: A total of 1,393 conserved and 84 novel miRNAs were successfully 
      discovered. In two separate batches, a total of 27 differentially expressed 
      miRNAs (11 up-regulated and 16 down-regulated) were observed in BCPAP cells after 
      SREBF1 interference with two distinct siRNA fragments, as compared to the control 
      siRNA treatment. Hsa-miR-941, hsa-miR-27a-5p, hsa-miR-29a-3p, hsa-miR-100-5p, and 
      hsa-miR-21-3p were selected for validation using qRT-PCR. The qRT-PCR results 
      were consistent with the sequencing data. Gene Ontology enrichment showed that 
      the predicted targets of these miRNAs were mainly involved in the regulation of 
      system development, metabolism and protein binding cellular processes, and 
      metabolic processes. Kyoto Encyclopedia of Genes and Genomes pathways analysis 
      showed that the predicted target genes were involved in several signaling 
      pathways, including the Ras, MAPK, insulin, thyroid hormone, and metabolic 
      pathway signaling pathways. CONCLUSION: Differentially expressed miRNAs and their 
      target genes may play an important role in the progression and prognosis of DTC 
      that is associated with SREBP1 expression.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Zhou, Jiating
AU  - Zhou J
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, P.R. China.
AD  - Institute of Clinical Pharmacology, Central South University and Hunan Key 
      Laboratory of Pharmacogenetics, Changsha, P.R. China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Changsha, P.R. China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, P.R. China.
FAU - Liu, Jianqiu
AU  - Liu J
AD  - Department of Pharmacy, People's Hospital of Rizhao, Shandong, P.R. China.
FAU - Zhang, K E
AU  - Zhang KE
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, P.R. China.
AD  - Institute of Clinical Pharmacology, Central South University and Hunan Key 
      Laboratory of Pharmacogenetics, Changsha, P.R. China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Changsha, P.R. China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, P.R. China.
FAU - Lv, Jing
AU  - Lv J
AD  - Department of Thyroid Surgery, Zhengzhou Central Hospital, Zhengzhou University, 
      Zhengzhou, P.R. China.
FAU - Peng, Xiaowei
AU  - Peng X
AD  - Department of Head and Neck Surgery, Hunan Cancer Hospital and the Affiliated 
      Cancer Hospital of Xiangya School of Medicine, Central South University, 
      Changsha, P.R. China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, P.R. China.
AD  - Institute of Clinical Pharmacology, Central South University and Hunan Key 
      Laboratory of Pharmacogenetics, Changsha, P.R. China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Changsha, P.R. China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, P.R. China.
FAU - Li, Zhi
AU  - Li Z
AD  - Department of Clinical Pharmacology, Xiangya Hospital, Central South University, 
      Changsha, P.R. China.
AD  - Institute of Clinical Pharmacology, Central South University and Hunan Key 
      Laboratory of Pharmacogenetics, Changsha, P.R. China.
AD  - Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry 
      of Education, Changsha, P.R. China.
AD  - National Clinical Research Center for Geriatric Disorders, Changsha, P.R. China.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Small Interfering)
SB  - IM
MH  - Humans
MH  - Sterol Regulatory Element Binding Protein 1/genetics
MH  - *MicroRNAs/genetics/metabolism
MH  - High-Throughput Nucleotide Sequencing/methods
MH  - RNA, Small Interfering
MH  - *Thyroid Neoplasms/genetics
MH  - Gene Expression Profiling/methods
OTO - NOTNLM
OT  - High-throughput sequencing
OT  - differentiated thyroid cancer
OT  - microRNAs
OT  - sterol regulatory element-binding proteins 1
EDAT- 2023/09/29 12:44
MHDA- 2023/10/02 06:42
CRDT- 2023/09/29 07:31
PHST- 2023/07/05 00:00 [received]
PHST- 2023/08/06 00:00 [revised]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/10/02 06:42 [medline]
PHST- 2023/09/29 12:44 [pubmed]
PHST- 2023/09/29 07:31 [entrez]
AID - 43/10/4435 [pii]
AID - 10.21873/anticanres.16639 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Oct;43(10):4435-4446. doi: 10.21873/anticanres.16639.